Modulation of Hormonal and Systemic Immunity by Hormonal Contraceptive Use
使用激素避孕药调节激素和全身免疫
基本信息
- 批准号:8318311
- 负责人:
- 金额:$ 49.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-27 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAllogenicAntigen-Presenting CellsAntiviral AgentsBiologicalBiopsyBloodCCL20 geneCCL3 geneCCL4 geneCD40 AntigensCD80 geneCD8B1 geneCXCL12 geneCellsCervicalCervix UteriContraceptive AgentsContraceptive UsageDendritic CellsDendritic cell activationDextransEnrollmentEpidemicEpidemiologyEpithelialEquilibriumEvaluationExposure toFeminizationGenital systemHIVHIV InfectionsHealth PersonnelHormonalIL8 geneImmune responseImmunityInfectionInflammatoryInjectableInterferonsInterleukin-1Interleukin-10Interleukin-12Interleukin-15Interleukin-6Intrauterine DevicesInvestigationLactoferrinLangerhans cellLevonorgestrelMeasuresMedroxyprogesterone 17-AcetateMemoryMethodsModelingMucous MembraneMusNatural ImmunityOralOral ContraceptivesPI3 genePermeabilityPharmaceutical PreparationsPoly I-CPredispositionProductionProgestinsRANTESRecommendationResearchResponse ElementsRiskRisk FactorsSurfaceSwabT-Cell DevelopmentT-Cell ProliferationT-LymphocyteTestingThickTissuesTumor Necrosis Factor-alphaUp-RegulationViralVirusVirus DiseasesVisitWomanadaptive immunityantileukoproteaseantimicrobialbasebeta-defensin-2chemokinecombatcomparativecytokinedextranfollow-uphormonal contraceptionhuman SLPI proteinhuman TLR3 proteinimprovednovelnovel strategiespandemic diseasepathogenreceptorresponsetransmission process
项目摘要
DESCRIPTION (provided by applicant): Modulation of mucosal and systemic immunity by hormonal contraceptive use ABSTRACT Growing feminization of the HIV pandemic has created an even greater need for research that will improve our understanding of risk factors promoting transmission of HIV to women. Many epidemiological investigations indicate there may be connections between hormonal contraceptive use and enhanced susceptibility for HIV acquisition, but substantial study limitations hypothesis of our proposal is that progestin-based
hormonal contraceptives inhibit genital tract immune responses and tip the balance of protective immunity at genital mucosal surfaces towards acquisition of infection. This hypothesis is based on novel demonstration in our murine model of viral mucosal infection that dendritic cell (DC) activation, virus-specific T cell expansion, and memory T cell development are suppressed among mice administered depot-medroxyprogesterone acetate (DMPA) prior to infection. Notably, our preliminary studies were able to demonstrate that antigen presenting cells (APCs) activated directly ex vivo from women using DMPA also have a decreased ability to induce allogeneic T cell proliferation. These results helped generate a fresh approach to this research question that focuses on the immunomodulatory effects of DMPA, oral contraceptives (OC), and levonorgestrel-containng intrauterine devices (LNG-IUD) that may impair host responses against viral pathogens. Incorporating methods similar to ones developed in our preliminary investigations, we will utilize APCs isolated from the blood and cervixes of women before (enrollment) and after (1 month follow-up visit) they initiate use of OC, DMPA, or LNG-IUD in order to determine the effects of these drugs on APC ability to up-regulate co-stimulatory molecule expression and induce ex vivo T cell proliferation (Aim 1). Cervical secretions collected from women at both study visits will be used to compare concentrations of several innate immune response elements, while cervical tissue will also be used to compare inflammatory and antiviral cytokine production by cervical cells stimulated ex vivo with a Toll-lik receptor 3 agonist (Aim 2). In Aim 2, we will also determine if OC, DMPA, or LNG-IUD use elicits any decreases in cervical epithelial layer thickness or any increases in the exposure of Langerhans cells to the mucosal surface. Completion of these research aims would provide the first comparative evaluation of the capacity of OCP, DMPA, and LNG-IUD to suppress host responses needed to combat genital tract infection, and would also supply healthcare providers more informed recommendations regarding the most appropriate choices for hormonal contraception among women at risk for HIV.
PUBLIC HEALTH RELEVANCE: Increasing feminization of the HIV epidemic demands more complete delineation of the relationships between hormonal contraceptive use and susceptibility to HIV infection. This project investigates changes to systemic and genital tract immune responses elicited by oral, injectable, and intrauterine hormonal contraceptives that may impair a woman's ability to combat viral infection. Completion of this proposal will determine biological plausibility of suspected associations between hormonal contraceptive and increased susceptibility to HIV, and supply healthcare providers more informed recommendations regarding apt hormonal contraceptive choices among women at risk for HIV infection.
说明(申请人提供):激素避孕药对粘膜和全身免疫的调节摘要HIV流行的女性化趋势日益增长,这就更需要进行研究,以提高我们对促进HIV向女性传播的危险因素的理解。许多流行病学调查表明,激素避孕药的使用与艾滋病毒感染易感性增强之间可能存在联系,但大量的研究局限性 我们建议假设是孕激素为基础的
激素避孕药抑制生殖道免疫反应,并使生殖器粘膜表面的保护性免疫平衡倾向于获得感染。这一假设是基于我们的病毒粘膜感染小鼠模型中的新证据,即在感染前给予醋酸甲羟孕酮(DMPA)的小鼠中,树突状细胞(DC)活化、病毒特异性T细胞扩增和记忆性T细胞发育受到抑制。值得注意的是,我们的初步研究能够证明,直接从使用DMPA的女性体内激活的抗原呈递细胞(APC)也具有降低的诱导同种异体T细胞增殖的能力。这些结果有助于产生一个新的方法来解决这个研究问题,重点是DMPA,口服避孕药(OC)和含左炔诺孕酮宫内节育器(LNG-IUD)的免疫调节作用,可能会损害宿主对病毒病原体的反应。与我们的初步研究中开发的方法类似的方法,我们将利用在开始使用OC、DMPA或LNG-IUD之前(登记)和之后(1个月随访)从妇女的血液和宫颈分离的APC,以确定这些药物对APC上调共刺激分子表达和诱导离体T细胞增殖的能力的影响(目的1)。在两次研究访视时从女性收集的宫颈分泌物将用于比较几种先天免疫应答元件的浓度,而宫颈组织也将用于比较用Toll样受体3激动剂离体刺激的宫颈细胞产生的炎症和抗病毒细胞因子(Aim 2)。在目标2中,我们还将确定OC、DMPA或LNG-IUD是否会导致宫颈上皮层厚度减少或粘膜表面朗格汉斯细胞暴露增加。这些研究目标的完成将提供OCP,DMPA和LNG-IUD抑制对抗生殖道感染所需的宿主反应的能力的第一次比较评估,并且还将为医疗保健提供者提供关于HIV风险妇女中激素避孕的最适当选择的更明智的建议。
公共卫生相关性:艾滋病毒流行病的女性化日益严重,这要求更全面地说明使用激素避孕药与易感染艾滋病毒之间的关系。该项目调查了口服、注射和宫内激素避孕药引起的全身和生殖道免疫反应的变化,这些免疫反应可能会损害妇女对抗病毒感染的能力。完成这一提案将确定激素避孕药和艾滋病毒易感性增加之间的可疑关联的生物可接受性,并为医疗保健提供者提供关于艾滋病毒感染风险妇女适当激素避孕药选择的更明智的建议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas L. Cherpes其他文献
Use of calibrated filter paper to evaluate vaginal moisture in mice
- DOI:
10.1038/s41598-025-02480-3 - 发表时间:
2025-05-30 - 期刊:
- 影响因子:3.900
- 作者:
Mohan Liu;Joseph G. Charek;Rose Kurian;Rodolfo D. Vicetti Miguel;Thomas L. Cherpes - 通讯作者:
Thomas L. Cherpes
Thomas L. Cherpes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas L. Cherpes', 18)}}的其他基金
Developing a nonsteroidal and nonhormonal agent that reverses menopause-related loss of genital epithelial integrity and function
开发一种非类固醇和非激素药物,可逆转更年期相关的生殖器上皮完整性和功能丧失
- 批准号:
10901049 - 财政年份:2023
- 资助金额:
$ 49.74万 - 项目类别:
Estrogen reverses progestin-mediated loss of genital mucosal barrier function
雌激素逆转孕激素介导的生殖器粘膜屏障功能丧失
- 批准号:
10024512 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Estrogen reverses progestin-mediated loss of genital mucosal barrier function
雌激素逆转孕激素介导的生殖器粘膜屏障功能丧失
- 批准号:
10412065 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Estrogen reverses progestin-mediated loss of genital mucosal barrier function
雌激素逆转孕激素介导的生殖器粘膜屏障功能丧失
- 批准号:
10172944 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Estrogen reverses progestin-mediated loss of genital mucosal barrier function
雌激素逆转孕激素介导的生殖器粘膜屏障功能丧失
- 批准号:
10458240 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Estrogen reverses progestin-mediated loss of genital mucosal barrier function
雌激素逆转孕激素介导的生殖器粘膜屏障功能丧失
- 批准号:
9769814 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Modulation of hormonal and systemic immunity by hormonal contraceptive use
使用激素避孕药调节激素和全身免疫力
- 批准号:
8659112 - 财政年份:2013
- 资助金额:
$ 49.74万 - 项目类别:
Modulation of hormonal and systemic immunity by hormonal contraceptive use
使用激素避孕药调节激素和全身免疫力
- 批准号:
8606863 - 财政年份:2013
- 资助金额:
$ 49.74万 - 项目类别:
Modulation of Hormonal and Systemic Immunity by Hormonal Contraceptive Use
使用激素避孕药调节激素和全身免疫
- 批准号:
8462133 - 财政年份:2012
- 资助金额:
$ 49.74万 - 项目类别:
Tregs:sculpting a balance between protection and pathology during viral infection
Tregs:在病毒感染期间塑造保护与病理之间的平衡
- 批准号:
8090575 - 财政年份:2010
- 资助金额:
$ 49.74万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 49.74万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 49.74万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 49.74万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 49.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)